Smartphone-based atrial fibrillation screening in the general population: feasibility and impact on medical treatment.

The aim of this study is to determine the feasibility, detection rate, and therapeutic implications of large-scale smartphone-based screening for atrial fibrillation (AF). Subjects from the general population in Belgium were recruited through a media campaign to perform AF screening during 8 consecutive days with a smartphone application. The application analyses photoplethysmography traces with artificial intelligence and offline validation of suspected signals to detect AF. The impact of AF screening on medical therapy was measured through questionnaires. Atrial fibrillation was detected in the screened population ( Smartphone-based AF screening is feasible at large scale. Screening increased OAC uptake and impacted therapy of both new and previously diagnosed clinical AF but failed to impact risk factor management in subjects with subclinical AF.

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.

Déclaration de conflit d'intérêts

Conflict of interest: H.G. is supported as pre-doctoral strategic basic research fellow by the Fund for Scientific Research Flanders (FWO 1S83221N). F.H.V. is supported by the Special Research Fund (BOF) of Hasselt University (BOF19PD04). T.P and S.E. reported serving as employees for Qompium NV, the company that holds the exclusive rights to FibriCheck©. P.VDV. holds personal stock in Qompium NV (Belgium) and participates an unpaid role in the advisory board of Qompium. P.V. receives fees form Daiichi-Sankyo, Boehringer Ingelheim, and Pfizer. M.R. receives fees from Novartis and Bayer. No other conflicts of interest were reported.